


June 16, 1985



The Chief
Division of Fuel Cycle and Material Safety
U.S. Nuclear Regulatory Commission
Region IV, 611 Ryan Plaza Drive, Suite 1000
Arlington, Tx 76011

Attention: Mr. Charles Cain

Subject: Amendmend to NRC License No: 35-23169-01
to include the provisions of GROUP IV
limited to the use of Indine - 131 for treatment
of hyperthyroidism.

Dear Sir,

Please amend the license to include the use of only Iodine-131 for the treatment of hyperthyroidism on out patient basis. The unit doses of Iodine 131 will purchased through the University of Oklahoma, Nuclear Pharmacy. The traetment doses will be limited to the amount which does not require hospitalization. Maximum one time possession limit of 30 milli Ci is requested. Dr chester L. Bynum, M.D., holds prior authorization for Group IV under NRC license No: 35-14145-01. Copy of this NRC license has been filed with the original application of NRC license No: 35-23169-01. Dr. Glenna Young's pertinent experience for this group has also been filed in the original application. A check for \$120/- is enclosed for the the amendmend fee.

Please let me know if any other information is required.

Thank you,

Sincerely Yours,

B. Wally Ahluwalia

B. Wally Ahluwalia, Ph.D.
Radiological Physicist

for Dr. Chet Bynum, M.D.
Radiology Office
Physicians Medical Park
Building 300
13301 North Meridian
Oklahoma City, Oklahoma 73120

June 2 IV

Applicant
Check No.	651
Amount/Fee Category	120 - 7C
Type of Fee	Amend
Date Check Rec'd	6/24/85
Received By	Jacques

8508290063 850731
REG4 LIC30
35-23160-01 PDR

460684